LEADER 03627nam 22005774a 450 001 9910143266303321 005 20170816142734.0 010 $a1-280-19728-5 010 $a9786610197286 010 $a0-470-79102-0 010 $a0-470-99471-1 010 $a1-4051-4097-6 035 $a(CKB)1000000000351278 035 $a(EBL)233111 035 $a(OCoLC)437147415 035 $a(SSID)ssj0000150751 035 $a(PQKBManifestationID)11162908 035 $a(PQKBTitleCode)TC0000150751 035 $a(PQKBWorkID)10281330 035 $a(PQKB)11450239 035 $a(MiAaPQ)EBC233111 035 $a(EXLCZ)991000000000351278 100 $a20040608d2004 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aEvaluating pharmaceuticals for health policy and reimbursement$b[electronic resource] /$fedited by Nick Freemantle and Suzanne Hill 210 $aMalden, Mass. $cBMJ Books/Blackwell Pub.$d2004 215 $a1 online resource (280 p.) 300 $aDescription based upon print version of record. 311 $a0-7279-1784-6 320 $aIncludes bibliographical references and index. 327 $aDevelopment of marketing authorisation procedures for pharmaceuticals / Alar Irs, Truus Janse de Hoog, Lembit Ra?go -- Interpreting clinical evidence / Nick Freemantle ... [et al.] -- International pharmaceutical policy: health creation or wealth creation? / Karen Bloor, Alan Maynard -- Development of fourth hurdle policies around the world / Rod S. Taylor ... [et al.] -- Economic modelling in drug reimbursement / Glenn Salkeld, Nick Freemantle, Bernie O'Brien -- Priority setting in health care: matching decision criteria with policy objectives / Gina Brinsmead, Alan Williams -- Tensions in licensing and reimbursement decisions: the case of riluzole for amyotrophic lateral sclerosis / Stirling Bryan ... [et al.] -- 327 $aRelationships between stakeholders: managing the war of words / Suzanne Hill, Kees de Joncheere -- Medicine and the media: good information or misleading hype? / Ray Moynihan, Lisa M. Schwartz, Steven Woloshin -- How to promote quality use of cost-effective medicines / Hans Hogerzeil, Kathleen Holloway -- Using economic evaluation to inform health policy and reimbursement: making it happen and making it sustainable / Andrew Mitchell -- Pricing of pharmaceuticals / David Newby, Andrew Creese, Alan Stevens -- Evaluating pharmaceuticals for health policy in low and middle income country settings / Andrew Creese ... [et al.]. 330 $a"The challenge in all settings is to make the difficult decisions in a way that is defensible, justifiable, ethical, and equitable" So write Nick Freemantle and Suzanne Hill in their introduction to this important discussion on decision making in the reimbursement of pharmaceuticals. Based around a programme supported by the World Health Organization, chapters by leading academics involved in the research tackle such major issues as international pharmaceutical policy, tensions in licensing policies, priority setting, and relationships between the stakeholders. 606 $aPharmaceutical policy 608 $aElectronic books. 615 0$aPharmaceutical policy. 676 $a362.17/82 676 $a362.1782 701 $aFreemantle$b Nick$0983439 701 $aHill$b Suzanne$0877980 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910143266303321 996 $aEvaluating pharmaceuticals for health policy and reimbursement$92245004 997 $aUNINA